Table 4.
Descriptive characteristics of the study population, stratified by the frequency of undergoing visual field testing. Categorical variables presented as counts (%), continuous variables presented as median (intra-quartile range).
| 0 VFT/year | >0 to <0.9 VFT/year | ≥0.9 to ≤1.1 VFT/year | >1.1 to ≤2.1 VFT/year | >2.1 VFT/year | Full cohort | |
|---|---|---|---|---|---|---|
| N | 33267 (8.75%) | 259349 (68.24%) | 42129 (11.09%) | 42301 (11.13%) | 2983 (0.78%) | 380029 (100%) |
| Age | 73 (59–82) | 67 (57–77) | 66 (57–75) | 66 (58–75) | 66 (57–74) | 67 (57–77) |
| Sex | ||||||
| Female | 19221 (57.78%) | 141579 (54.59%) | 22308 (52.95%) | 22771 (53.83%) | 1553 (52.06%) | 207432 (54.58%) |
| Male | 14046 (42.22%) | 117770 (45.41%) | 19821 (47.05%) | 19530 (46.17%) | 1430 (47.94%) | 172597 (45.42%) |
| Residence location | ||||||
| Rural | 5542 (16.66%) | 36190 (13.95%) | 5331 (12.65%) | 4512 (10.67%) | 280 (9.39%) | 51855 (13.65%) |
| Urban | 27725 (83.34%) | 223159 (86.05%) | 36798 (87.35%) | 37789 (89.33%) | 2703 (90.61%) | 328174 (86.35%) |
| Ocular comorbidities | ||||||
| Diabetic retinopathy | 2789 (8.38%) | 18424 (7.1%) | 2494 (5.92%) | 2705 (6.39%) | 181 (6.07%) | 26593 (7%) |
| Macular degeneration | 8154 (24.51%) | 50501 (19.47%) | 8201 (19.47%) | 9263 (21.9%) | 710 (23.8%) | 76829 (20.22%) |
| Number of types of glaucoma medications prescribed | ||||||
| 0 | 11732 (35.27%) | 65855 (25.39%) | 8151 (19.35%) | 7832 (18.51%) | 557 (18.67%) | 94127 (24.77%) |
| 1 | 10747 (32.31%) | 88819 (34.25%) | 12651 (30.03%) | 9594 (22.68%) | 467 (15.66%) | 122278 (32.18%) |
| 2 | 6128 (18.42%) | 56261 (21.69%) | 9996 (23.73%) | 9406 (22.24%) | 537 (18%) | 82328 (21.66%) |
| ≥3 | 4660 (14.01%) | 48414 (18.67%) | 11331 (26.9%) | 15469 (36.57%) | 1422 (47.67%) | 81296 (21.39%) |
| Receipt of incisional glaucoma surgery | ||||||
| Yes | 381 (1.15%) | 6604 (2.55%) | 1964 (4.66%) | 3414 (8.07%) | 378 (12.67%) | 12741 (3.35%) |
VFT=Visual field tests